|Articles|February 1, 2002

Optimal Cholesterol Management: New Strategies
Volume 8
Issue 2 Suppl

Preclinical and Clinical Pharmacology of a New Class of Lipid Management Agents

Author(s)Lawrence L. Rudel, PhD

Download PDF: Preclinical and Clinical Pharmacology of a New Class of Lipid Management Agents

Articles in this issue

almost 24 years ago

Article

Participating Faculty

almost 24 years ago

Article

Introduction

almost 24 years ago

Article

Rising to the Challenge of the New NCEP ATP III Guidelines: Exceeding Current Therapeutic Limitations

almost 24 years ago

Article

State of the Art in Cholesterol Management: Targeting Multiple Pathways

almost 24 years ago

Article

An Investigative Look: Selective Cholesterol Absorption Inhibitors - Embarking on a New Standard of Care

almost 24 years ago

Article

Future Outlook: Changing Perspectives on Best Practice

almost 24 years ago

Article

Panel Discussion

almost 24 years ago

Article

Continuing Medical Education Quiz

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

A Health Economic Evaluation of Digital Digestive Care Management

ByMartha Shepherd, DO, MPH,Pen-Che Ho, MS,David Hines, BA,Jon Harris-Shapiro, BA,Dena Bravata, MD, MS,Christopher M. Whaley, PhD,K. Davina Frick, PhD,Emmanuel F. Drabo, PhD,Ron Z. Goetzel, PhD

January 21st 2026

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

ByShamsi Atefeh, PhD

January 15th 2026

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

ByMohamed M. Ali, MS,Scott Lunos, MS,Zachary Henderson, BSB,Michele Allen, MD, MS,Patricia Adam, MD, MSPH,Genevieve B. Melton, MD, PhD,Rubina Rizvi, MD, PhD

January 12th 2026

Subjective and Objective Impacts of Ambulatory AI Scribes

ByJulia Adler-Milstein, PhD,Orianna DeMasi, PhD,Hossein Soleimani, PhD,Sarah Beck, MDiv,Maria E. Byron, MD,Aris Oates, MD,Robert Thombley, BS,Jinoos Yazdany, MD, MPH,Sara G. Murray, MD, MAS

January 8th 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Preclinical and Clinical Pharmacology of a New Class of Lipid Management Agents

Articles in this issue

Newsletter

Related Content

Specialty and Operator Status Influence Electronic Health Record Use Variation

A Health Economic Evaluation of Digital Digestive Care Management

Empowering Children and Parents Through Technology: Opportunities, Challenges, and Future Directions

Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data

Subjective and Objective Impacts of Ambulatory AI Scribes

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care

Semaglutide Shows Promise for Steatohepatitis Resolution in MASH

Advancing Biomarker Testing Across GU, Lung, and Myeloma Care

Socioeconomic Factors Linked to Surgical Outcomes in Upper Extremity Soft Tissue Sarcoma

RWD Is Transforming Mental Health, Neurology Managed Care: Mitzi Wasik, PharmD